Novo Nordisk has submitted an unsolicited bid to buy obesity biotech Metsera out from under Pfizer, offering $6 billion ...

Shares of Danish rival Novo Nordisk slipped after it sought to snatch Pfizer target Metsera from the American drug giant's arms. Novo launched an unsolicited bid valued at up to $9 billion for obesity ...

A bitter takeover battle has erupted in the fat jab market after Danish drug giant Novo Nordisk gatecrashed a takeover deal ...

Lilly’s quarterly results Thursday, combined with Novo Nordisk’s unsolicited offer for a startup, confirm the $72 billion ...

The drugmaker issued the recall voluntarily after determining higher-than-acceptable levels may be present in some products.

Novo Nordisk faces headwinds from regulatory uncertainty, competitive efficacy gaps with Eli Lilly and technical downward ...

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled to $3.57 billion in the third quarter. Meanwhile, revenue ...

Danish pharmaceutical giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, announced Thursday an unsolicited bid to acquire obesity treatment maker Metsera, topping an offer from US ...

US President Trump wraps up his Asia tour with major trade and security announcements, while Israel’s Netanyahu issues a ...

Denmark's Novo Nordisk said on Thursday it has made an unsolicited bid for U.S. drug maker Metsera , after Pfizer in ...

Por TOM MURPHYEl mercado de tratamientos para la obesidad y la diabetes sigue siendo extremadamente activo, canalizando miles de millones de dólares en ventas para Eli Lilly y alimentando una ...